GlassScriptPhysician profile
Scott J Taylor
NPI 1295062057
$71,027.62
in general payments reported to CMS, 2019-2025
32 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,035 · 2022: $2,067 · 2023: $5,992 · 2024: $14K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $21K · Consulting Fee: $9,385 · Travel and Lodging: $6,336 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,960.00 |
| Food and Beverage | $20,761.08 |
| Consulting Fee | $9,385.00 |
| Travel and Lodging | $6,335.77 |
| Education | $484.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26,094.41 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $11,720.25 | 2023-2025 | Zoryve |
| Ucb, INC. | $11,358.70 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $3,865.06 | 2021-2025 | |
| Genzyme Corporation | $3,852.76 | 2021-2025 | |
| Leo Pharma INC. | $2,571.66 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $2,325.22 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $1,523.25 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,243.83 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,212.21 | 2021-2025 | |
| Incyte Corporation | $1,016.12 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $863.24 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $811.34 | 2022-2025 | |
| Dermavant Sciences, INC. | $481.76 | 2023-2024 | Vtama |
| Organogenesis INC. | $435.59 | 2023-2025 | Via Matrix, Cygnus Dual, Affinity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $411.50 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $342.47 | 2024-2025 | |
| Organon LLC | $205.03 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $164.36 | 2022-2024 | |
| Amgen INC. | $161.22 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.34 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Helsinn Therapeutics (U.S.), INC. | $51.01 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $32.48 | 2024 | Dupixent |
| Nobelpharma America, LLC | $32.08 | 2025 | |
| Medtronic, INC. | $28.88 | 2025 | Venaseal |
| Krystal Biotech INC | $28.56 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.58 | 2025 | Spevigo |
| Biowound Solutions, INC. | $26.98 | 2025 | Bio-Connekt |
| Smith+Nephew, INC. | $26.95 | 2023 | Grafix Pl |
| Almirall LLC | $25.24 | 2021 | |
| Genentech USA, INC. | $15.91 | 2022 | |
| Biofrontera INC. | $10.63 | 2024 | Rhodoled Xl, Ameluz, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.